Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. - Wikidata - awgldk - TriplyDB

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

http://www.wikidata.org/entity/Q33232426

about

Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells Beyond CA125: the coming of age of ovarian cancer biomarkers Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer.Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.Glucocorticoid-induced reversal of interleukin-1β-stimulated inflammatory gene expression in human oviductal cells.Phase II biomarker trial of a multimarker diagnostic for ovarian cancer Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy.Prognostic biomarkers in ovarian cancer.A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation Early detection of ovarian cancer CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis Reliability of tumor markers, chemokines, and metastasis-related molecules in serum.Exploring the immunoproteome for ovarian cancer biomarker discovery.Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays Potential markers for detection and monitoring of ovarian cancer.Early inflammatory response in epithelial ovarian tumor cyst fluids.Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients.Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction.Microenvironment and pathogenesis of epithelial ovarian cancer Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis.Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis Recent technical strategies to identify diagnostic biomarkers for ovarian cancer.Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics.Usage of cancer associated autoantibodies in the detection of disease p53 autoantibodies, cytokine levels and ovarian carcinogenesis Autoantibodies as biomarkers for ovarian cancer.Aberrant tumor-associated antigen autoantibody profiles in healthy controls detected by multiplex bead-based immunoassay.Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma.Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.Chemokine receptors in epithelial ovarian cancer Hypoxia promotes the proliferation of cervical carcinoma cells through stimulating the secretion of IL-8.Clinical application of proteomics in ovarian cancer prevention and treatment.

P2860

Q21254653-FE364381-DE57-4A14-9551-5B752366D104 Q24651567-8CA2A63B-903A-45C4-8A78-057B873CDCE3 Q33320360-6CF6D961-EAE1-4003-8FDC-A9AEE8B8D8EF Q33601372-1DE25C6F-41F6-4752-9A87-3ED2E815E602 Q33608271-48034CDE-422E-4DC0-B52E-9CFDD5416AFE Q33633387-A448D433-667B-4612-9598-486F56C9ED8F Q33645478-05E53BA6-E082-4A93-9167-A2D7D7930032 Q33868802-057ECB0B-3C09-4C97-B7E8-AD903A838168 Q34048965-6E8D7271-577D-4072-B7DF-F2C382B6E1AB Q34086636-494BD871-DE76-4A51-BDA7-30A55FE2CEEA Q34087776-94CB1DAB-514D-4E2B-9432-309269BD5396 Q34094731-B68D464B-4109-471E-87D8-B8369B6E617E Q34095143-1ED6D32A-71C7-46BC-B315-CA46E43FD2D8 Q34285076-877D43DE-CFB4-4ED7-8A8D-C7ECC94F9B9E Q34402670-C48DB0AB-C422-465D-AB40-5329B1596AD0 Q34578119-60E0000A-01D0-4C0D-BF74-A200A666BB5A Q34624404-71AD5C4C-347A-4144-A2BF-22E39EF13125 Q34705309-73E84929-7F44-423F-8FE8-FD08238FAB07 Q34960174-3FDCC99E-552E-4842-8649-9DF4A83F0C55 Q34998539-C3A8A2A0-D329-4AAB-A430-35B1BC5D4032 Q35104034-6DC4D0E5-8CE4-4337-B10E-304A6BF374AE Q35294515-67626421-35A0-4610-85A6-6B80E9B49F80 Q35419057-2712CFEF-F89B-458C-B63A-A99E91E700C4 Q35659991-A50DE764-E082-4EDF-AE6D-352DA0E0D846 Q36234132-2D60E0C3-DAB6-464C-B7FE-B143E88AC2DB Q36394694-22774891-DEFA-472A-9168-D2EB5AE91827 Q36731399-56EDAF79-7DC7-4590-906B-A8D442AC5AB7 Q37106945-CE8F3CE0-5947-490F-B597-004227114737 Q37217734-58466865-42F4-4C8E-A8B6-C62F1A44A6A7 Q37223836-665E86CA-040C-48E2-ABB6-4A7DB7A31D81 Q37224335-EB2865CE-19BD-4811-8428-5C9196A024F0 Q37253388-5787992F-94B3-4925-BECA-F49F237C5DBD Q37340624-5B670DAD-DF66-431C-A2AE-3D5F5FFFF0F8 Q37390397-6C0EC1EB-4E25-40D7-9068-05FF670AD1AF Q37405207-70253E3D-98CF-4F69-806E-45904D6C5EF3 Q37437224-1E1A5148-1448-4691-AAD2-0CD138C8ABAC Q37480340-77AC5F33-D434-47EB-A2A6-59E902579A0F Q37535454-1DE82472-C7F7-4BF4-86AB-4DA79A90C015 Q37587351-4CF881CB-515B-4D42-9EFE-6A82262AA406 Q37605790-D0C3907D-F587-4620-82A3-30332E1734C0

P2860

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

http://www.wikidata.org/entity/Q33232426

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

@ast

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

@en

type

label

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

@ast

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

@en

prefLabel

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

@ast

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

@en

P1433

Q33232426-E0DFB95B-2D21-487B-9A90-BC37102BBDA1

P1476

Q33232426-CDD7A152-5557-4745-A3AC-E41721194705

P2093

Q33232426-0475FE38-71D5-4324-AD88-3023F2D92F95

Q33232426-128A4048-36C0-40FD-89C4-F57B788D3A2B

Q33232426-222463E7-2E8A-42AC-A65E-6DD02155B139

Q33232426-24442EFB-F2EB-469E-8E4A-F2D43AC973CA

Q33232426-3CA01068-3CD0-4FEB-9F53-FA6EDDB47DC6

Q33232426-C56C9CE8-AA08-4FDC-B0CD-BF2DBA38581F

Q33232426-E174F404-ED2C-4A61-9B0E-6253D64CD5E4

P304

Q33232426-B2874D0F-5E75-4B4F-88BA-F61C56792697

P31

Q33232426-F122608D-9169-4CD7-8333-B4CB0B67DA84

P356

Q33232426-7EC7D283-FAD2-495A-9B7A-B067CBA4DC3C

P407

Q33232426-341DDEBD-489B-459D-AC10-622BA97C85C6

P433

Q33232426-8993AC14-5CD3-43DE-B5F2-00602B92153F

P478

Q33232426-C0D418B0-A6C7-4425-8E4C-445D0BB81BF8

P50

Q33232426-CECBA915-583A-407C-85E2-BDD0AFB89EEB

P577

Q33232426-8096D667-F3F1-4C57-A6FF-091299B9829D

P698

Q33232426-D03A20F1-F3CE-4FE3-A770-B08661D53821

P921

Q33232426-10674800-65E2-4AEF-9F24-EC4DCD971D3F

Q33232426-FD0F3925-B6DB-4F0C-B25C-E72E091B45BE

P356

J.YGYNO.2005.12.011

P1433

Gynecologic Oncology

P1476

Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

@en

P2093

Adele M Marrangoni

http://www.w3.org/2001/XMLSchema#string

Anna E Lokshin

http://www.w3.org/2001/XMLSchema#string

Brian M Nolen

http://www.w3.org/2001/XMLSchema#string

Douglas Landsittel

http://www.w3.org/2001/XMLSchema#string

Elieser Gorelik

http://www.w3.org/2001/XMLSchema#string

Lyudmila Velikokhatnaya

http://www.w3.org/2001/XMLSchema#string

Mathew Winans

http://www.w3.org/2001/XMLSchema#string

P304

244-251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2005.12.011

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Francesmary Modugno

P577

2006-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16434085

http://www.w3.org/2001/XMLSchema#string

P921